The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates

G Jansen, R Pieters

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Impaired transport appears to be a common mechanism of resistance of neoplastic cells to the antifolate methotrexate. The extensive knowledge of the molecular, biochemical and functional properties of the membrane transport systems for folates, in particular the reduced folate carrier (RFC) and membrane folate receptors (MFR), has made an important contribution to the rational design of novel antifolates that are either more efficiently internalized via these transporters or can simply bypass these transport routes. The current status of exploiting the RFC and MFR for transport of novel antifolates active in preclinical model systems and a clinical setting will be reviewed, with a special reference to childhood acute lymphoblastic leukemia (ALL) and acute non-lymphoblastic leukemia (ANLL).

Original languageEnglish
Pages (from-to)211-8
Number of pages8
JournalDrug Resistance Updates
Volume1
Issue number3
Publication statusPublished - 1998

Cite this